Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

GSK Launches Triple-Therapy HIV Drug in China at a Low-Cost $450/Month

publication date: Jan 24, 2018

GlaxoSmithKline has launched Triumeq, a triple-therapy antiretroviral treatment for HIV, in China at a monthly price of $450. That price is lower than in South Korea, Taiwan and Hong Kong, GSK said. It is also an 85% discount to the usual price of $2900/month in the US. In China, Triumeq is distributed by ViiV Healthcare, a JV majority owned by GSK along with minority shareholders Pfizer and Japan’s Shionogi. More details....

Stock Symbols: (NYSE: GSK) (NYSE: PFE)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China